Cytomegalovirus (CMV)

CAS No.	Product Name	Inquiry
	Ganciclovir-d5 Ganciclovir-d5 (BW 759-d5) is the deuterium labeled Ganciclovir. Ganciclovir (BW 759), a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovir also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir has an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1).
	HBA(111-142)
10212-25-6	2,2'-Cyclocytidine hydrochloride 2,2'-Anhydro-cytidine-HCl is a DNA synthesis inhibitor commonly used as an antineoplastic agent to treat leukemias.
107910-75-8	Ganciclovir Sodium Ganciclovir Sodium is a potent inhibitor of the Herpesvirus family including cytomegalovirus. It is an acyclovir analog. It is used to treat complications from AIDS-associated cytomegalovirus infections. It was developed by Roche and has been listed.
1113044-49-7	FIT-039 FIT-039 is a potent and selective inhibitor of cyclin-dependent kinase 9 (CDK9), which suppresses replication of a broad spectrum of DNA viruses through inhibition of mRNA transcription.
113852-41-8	PMEDAP PMEDAP is a potent inhibitor of human immunodeficiency virus (HIV) replication with anti-murine cytomegalovirus (MCMV) activity, and is a very potent inhibitor of moloney murine sarcoma virus (MSV)-induced tumor formation and associated mortality. It has been studied for potential treatment of feline herpesvirus 1 (FHV-1).
1177798-88-7	BRACO 19 trihydrochloride BRACO 19 trihydrochloride is a telomerase inhibitor (IC50 = 115 nM) that suppresses the expression of human telomerase reverse transcriptase (hTERT) and induces cellular senescence. BRACO 19 was shown to inhibit growth of uterine cancer cells in vitro and growth of uterine tumor xenografts in mice.
1189966-73-1	Ganciclovir-d5 Ganciclovir-[d5] is a labelled antiviral drug ganciclovir.
119139-23-0	3,4-Di(3-indolyl)-1H-pyrrole-2,5-dione Bisindolylmaleimide IV (BIM IV) is an inhibitor of pyruvate phosphate dikinase (PPDK). It is a cell-permeable potent and somewhat selective inhibitor of PKC with IC50 of 87 nM. BIM IV is a cell-permeable inhibitor of protein kinase C (PKC) with IC50 values reported to range from 0.10 to 0.55 µM. It also inhibits protein kinase A (PKA) with an IC50 of 2.7 μM.
1216540-18-9	BX-513 hydrochloride BX 513 hydrochloride is a selective CCR1 receptor antagonist (Ki = 0.04, > 10, > 10 and > 10 nM for CCR1, CCR5, CXCR2 and CXCR4 receptors, respectively), and also acts as a US28 agonist. It inhibits MIP-1α-induced intracellular calcium mobilization (IC50 = 2.5 μM).
127757-45-3	Cyclic-HPMPC Cyclic HPMPC is a potent antiviral agent. Cyclic HPMPC can increase arterial oxygen saturation levels in lethal vaccinia virus (IHD strain)-infected mice. Cyclic HPMPC improves the outcome of congenital guinea pig cytomegalovirus (GPCMV) infection and decreases viral replication in guinea pig model.
1359968-33-4	Ganciclovir-hydrate Ganciclovir (BW 759) hydrate, a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovirhydrate also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir hydrate inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir hydrate has an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1) and can diffuse into the brain.
138660-96-5	Sevirumab Sevirumab is a human IgG1 monoclonal antibody that targets human cytomegalovirus (HCMV). Sevirumab has been used for the treatment of infections with cytomegalovirus in patients with AIDS.
144245-52-3	Fomivirsen Fomivirsen is an antisense oligonucleotide, a synthetic 21 member oligonucleotide with phosphorothioate linkages (which are resistant to degradation by nucleases).
1222800-79-4	ML324 ML324 exhibits good Caco-2 cell permeability, and possesses excellent microsomal stability in the presence of both mouse and rat liver microsomes.
175865-59-5	Valganciclovir HCl Valganciclovir hydrochloride hydrate is an antiviral used to treat cytomegalovirus infection. It is the prodrug of ganciclovir, a synthetic analog of 2'-deoxy-guanosine which is phosphorylated to a dGTP analog that competitively inhibits the incorporation of dGTP by viral DNA polymerase.
113852-37-2	Cidofovir Cidofovir is inhibitory to CMV plaque formation even when added to the cells at 48 hr post infection with IC50 of 0.9 μg/mL for Davis and 1.6 μg/mL for AD-169 strains,respectively.
444805-28-1	CMX 001 CMX 001 is an antiviral inhibitor, working against BK polymavirus replication in primary human urothelial cells.An alkoxyalkyl ester prodrug containing the synthetic, acyclic nucleoside monophosphate analog cidofovir linked, through its phosphonate group, to a lipid, 3-hexadecyloxy-1-propanol, with antiviral activity against double-stranded DNA viruses.
917389-32-3	Letermovir Letermovir is a novel anti-CMV compound which targets the pUL56 (amino acid 230-370) subunit of the viral terminase complex and remains active against virus resistant to DNA polymerase inhibitors. It has a novel mode of action targets the enzyme UL56 terminase and keep active to other drug-resistant virus. It has been approved in prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT).
149394-66-1	Cidofovir dihydrate Cidofovir is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA polymerase and therefore prevention of viral replication and transcription. It is an acyclic nucleoside phosphonate, and is therefore independent of phosphorylation by viral enzymes, unlike acyclovir. Cidofovir was discovered at the Institute of Organic Chemistry and Biochemistry, Prague, and developed by Gilead Sciences and is marketed with the brand name Vistide by Gilead in the USA, and by Pfizer elsewhere. Maintenance therapy with cidofovir involves an infusion only once every two weeks, making it a convenient treatment option. Because dosing is relatively infrequent, a permanent catheter is not necessary for infusions.

※ Please kindly note that our services are for research use only.